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How do hematopoietic stem cells choose to be lymphocytes? In this issue of Immunity, Dias et al. (2008)
uncover the requirement for E2A during lymphoid-lineage priming in the multipotent progenitor population.Immunity 29, August 15, 2008 ª2008 Elsevier Inc. 169Hematopoietic stem cells (HSCs) can give
rise to all classes of hematopoietic cells,
which include almost all cell types in-
volved in both innate and adaptive immu-
nity. Hematopoietic cells are categorized
in either the lymphoid or the myeloid line-
age. Lymphoid-lineage cells, or lympho-
cytes, include T, B, and NK cells. Other
cell types, such as megakaryocytes and
erythrocytes (MegEs), as well as granulo-
cytes and macrophages (GMs), belong
to the myeloid lineage. Prospective isola-
tion of common lymphoid progenitors
(CLPs) and common myeloid progenitors
(CMPs) separated the lymphoid and mye-
loid lineages at the progenitor level early
on during the hematopoietic differentia-
tion program. A lot of effort has been spent
on characterizing developmental interme-
diates upstream of CLPs and CMPs so
that we can better understand how multi-
potent hematopoietic progenitors diverge
into the lymphoid and myeloid lineages.
Although we are getting an increasingly
nuanced understanding of the hematopoi-
etic tree, knowledge of the molecular
determinants governing this lineage-di-
versification process is still lacking. In
this issue of Immunity, Dias et al. (2008)
demonstrate that E2A is necessary for
lymphoid-lineage priming in the multi-
potent progenitor (MPP) population.
Analysis of MPPs downstream of HSCs
suggests that during lymphopoiesis, pro-
genitors undergo a stepwise lineage-
restriction process (Figure 1). MPPs first
lose MegE potential and then GM potential
before establishing lymphoid-lineage
commitment. CLP is the most immature
cell population identified, with differentia-
tion potential restricted to the lymphoid
lineage. However, expression of several
lymphoid-lineage-affiliated genes is acti-
vated prior to the CLP stage. This promis-cuous expression of lymphoid-affiliated
genes, or lymphoid-lineage priming, was
first described by Kincade and col-
leagues. Using RAG1-GFP knockin (KI)
mice, Kincade and colleagues character-
ized early lymphoid progenitors (ELPs),
which are GFPlo cells in the c-KithiLine-
ageSca-1+ (KLS) fraction (Igarashi et al.,
2002). These cells reside in the MPP pop-
ulation, have high lymphoid potential and
limited GM potential, and express multiple
lymphoid-affiliated genes, such as those
that encode TdT, IL-7Ra, and EBF, in
addition to RAG1. We and others have
subsequently characterized MPP subsets
with cell-surface markers such as Flt3 and
VCAM-1, which overlap with ELPs (Fig-
ure 1). Lymphoid-primed MPPs (LMPPs
or Flt3hiVCAM-1 MPPs) have lost MegE-
differentiation ability and are highly biased
toward lymphocyte differentiation in vivo
(Adolfsson et al., 2005; Lai and Kondo,
2006). Therefore, specification of MPPs
to the lymphoid lineage is thought to be
established in LMPPs. Promiscuous ex-
pression of lymphoid-affiliated genes
occurs at a very low level in LMPPs. It is
unclear whether lineage priming is simply
an indication of the presence of cells with
an activated lymphoid-differentiation pro-
gram or whether this process has impor-
tant implications for the lymphoid versus
myeloid cell-fate decision in MPPs. An-
other question is how lymphoid-lineage
priming is initiated in MPPs.
An E-box-binding transcription factor,
E2A, has been known to be necessary
for many aspects of T and B cell develop-
ment (reviewed in Murre, 2005). Dias et al.
reveal that lymphoid-progenitor popula-
tions upstream of T and B lineage com-
mitment are severely reduced in the
absence of E2A (Dias et al., 2008). Nota-
bly, the marked reduction in the numbersof hematopoietic progenitors is observed
first in the Flt3hi LSK fraction, which is
characterized as a LMPP and includes
lymphoid-specified VCAM-1 MPPs
(and ELPs). Interestingly, lymphoid-re-
lated genes that are upregulated in
LMPPs are not expressed in the absence
of E2A, suggesting that E2A expression is
necessary for priming of lymphoid-related
gene expression.
Other than E2A, Ikaros and PU.1 have
also been suggested as regulators of
lymphoid-lineage priming, a role that is
demonstrated in gene knockout mice as
well as with gene-marking methods
(Arinobu et al., 2007; Yoshida et al.,
2006). PU.1 expression is ubiquitously
observed in hematopoietic progenitors
at different levels (Arinobu et al., 2007).
PU.1 is upregulated in the MPP popula-
tion compared to HSCs. Although PU.1lo
MPPs show ‘‘classical’’ MPP activity sim-
ilar to Flt3loVCAM-1+ MPPs (Figure 1),
PU.1hi MPPs mark LMPPs, which have
lymphoid and GM potential without any
obvious MegE potential (Arinobu et al.,
2007). Similarly, upregulation of Ikaros ex-
pression also marks LMPPs in the KLS
fraction (Yoshida et al., 2006). E2A is
also ubiquitously expressed in HSCs. In
contrast to PU.1 and Ikaros, upregulation
of E2A expression is observed at the CLP
stage rather than at the LMPP stage.
Therefore, PU.1 and Ikaros might have
more active roles in priming lymphoid-re-
lated gene expression, whereas E2A may
play a role in the regulation of lymphoid
gene expression at a more basal level. In
fact, the gene-expression profile of
HSCs is also affected in E2A-deficient
mice (Dias et al., 2008).
Transcription factors form gene regula-
tory networks that have been well docu-
mented with respect to B cell lineage
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Kee, 2007). What is the relationship
between PU.1, Ikaros, and E2A in lym-
phoid-lineage priming? Although expres-
sion of many genes is affected in LMPPs in
the absence of E2A, expression of Ikaros
and PU.1 is normal (Dias et al., 2008).
Therefore, E2A may be a prerequisite for
global lymphoid-related gene expression,
but it cannot be a determinant or trigger
lymphoid-lineage priming at the LMPP
stage. Combination and ordered expres-
sion of these and other transcription
factors might be a key to initiating the lym-
phocyte developmental program prior to
lymphoid-lineage commitment.
Interpretation of results obtained in
gene-targeted mice needs to be done
carefully, especially when gene-expres-
sion patterns change. Characterizations
of cell populations are done by phenotyp-
ing with cell-surface markers and/or gene
marking with reporter genes, usually on
FACS. As shown by Dias et al., IL-7Ra
gene expression is downregulated in
LMPPs in the absence of E2A (Dias
et al., 2008). If E2A is necessary for proper
IL-7Ra expression, we may not observe
IL-7Ra-expressing cells in E2A-deficient
mice. In this case, it is not possible to
properly assess the function of CLPs in
the absence of E2A because IL-7Ra is
one of the markers used to define the
CLP population. Similarly, expression of
commonly used surface markers, such
as c-Kit and Sca-1, might be affected in
the absence of a certain transcription fac-
tor. Therefore, comparison of the popula-
tion with the same surface phenotype
from wild-type and gene-deficient mice
may not be necessarily meaningful. In
fact, the LMPP population cannot be
identified in Ikaros null mice by marking
Flt3hi KLS cells because Flt3 expression
is greatly downregulated in MPPs in the
absence of Ikaros (Yoshida et al., 2006).
Advances in our understanding of the
molecular mechanisms of lymphoid-line-
age specification and commitment are
largely dependent on the phenotypic char-
acterizations of bone-marrow populations
at the different maturational stages. Re-
cent progress in subfractionation and pre-
cise analyses of the differentiation poten-
Figure 1. E2A Has Multiple Roles at Various Stages during Lymphocyte Development
A recent model of early hematopoiesis is shown. Flt3loVCAM-1+ MPPs represent ‘‘classical’’ MPPs with
true multipotent-differentiation potential. The granulocyte-macrophage-lymphoid progenitor (GMLP)
overlaps greatly with Flt3hiVCAM-1+ MPP. Similarly, LMPP, ELP, and Flt3hiVCAM-1 MPP are thought
to reside in the same or mostly overlapping population. The stages in which E2A has a role are indicated
in this figure. GMP, granulocyte-macrophage progenitor; MEP, megakaryocyte-erythrocyte progenitor;
ETP, early T cell progenitor.
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progenitors make it possible to redefine
the true nature of the phenotypes of
gene-deficient mice that were previously
established. T and B cell development is
severely impaired in the absence of E2A.
Although E2A (and/or other E proteins) is
necessary for multiple different stages of
T and B cell development, the results by
Dias et al. suggest that lymphocyte devel-
opment is impaired at a much earlier stage
in E2A-deficient mice than previously be-
lieved (Dias et al., 2008; Murre, 2005).
Thus, it is likely that more genes, other
than E2A, PU.1, and Ikaros, might be in-
volved in lymphoid-lineage priming. What
is the relationship between E2A and other
genes? How is the expression of these
genes regulated? Does extracellular stim-
ulation play any roles in lymphoid-lineage
specification? For example, inflammation
induces emergency granulopoiesis at the
expense of B cell development in bone
marrow, a response that seems to be
caused by an altered bone-marrow micro-
environment (Ueda et al., 2005). It may not
be easy to fully understand the molecular
regulation of lymphoid-lineage priming
and commitment. Is it simpler or more
complex than we imagine now? The find-
ing by Dias et al. (2008) might just be the
beginning of a long journey toward the
goal of understanding how lymphoid and
myeloid homeostasis is maintained in vivo.
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